res of Sarepta Therapeutics nearly halved on Thursday after the meals and Drug management maintained its “poor” outlook on the employer‘s drug for an extraordinary muscle-wasting ailment. Sarepta stock closed down more than forty four percentage. Sarepta is seeking out